The French public health authority has advised against giving people under the age of 30 the Modern’s Covid-19 vaccine, citing higher risks of heart inflammation after vaccination. Instead, the body recommends Pfizer’s jab for this group.
Based on recently published data, the French health authority, Haute Autorite de Sante (HAS), said that the risk of myocarditis from Pfizer-BioNTech’s Comirnaty “seems to be about five times less … compared to Modernas Spikevax jab” in young people in a opinion published on Monday.
Cases of myocarditis occur mainly within seven days after vaccination, more often after the second dose, and in men under 30 years of age, the message read.
HAS, who advises the French health sector but does not have the power to ban drugs, said the recommendation would apply to the first and second doses, as well as a third “booster shot” while waiting for further data.
For the French population aged 30 and over, the body said it supported the administration of Spikevax in this group, stating that its effectiveness was slightly higher than Pfizer-BioNTech’s jab.
Last month, Nordic nations imposed various restrictions on Moderna’s vaccine. Iceland has made the widest launch of jab, with its health authorities stopping the use of the entire population.
Stockholm also announced that it would freeze the use of Moderna for the entire population born in 1991 and later. Helsinki followed suit, but stopped the inoculum for young male pimples only based on a study involving Finland, Denmark, Norway and Sweden which found that men under 30 had a slightly higher risk of developing myocarditis.
Oslo also suggests that young Norwegian men should consider choosing Comirnaty when deciding to be stabbed.
The European Medicines Agency announced that myocarditis and pericarditis would be added to the list of rare side effects of both Moderna and Pfizer-BioNTech mRNA vaccines in July. The medical watchdog insists that cases are extremely rare, however.